0001104659-22-092614.txt : 20220818 0001104659-22-092614.hdr.sgml : 20220818 20220818171538 ACCESSION NUMBER: 0001104659-22-092614 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220816 FILED AS OF DATE: 20220818 DATE AS OF CHANGE: 20220818 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Khattar Jack A. CENTRAL INDEX KEY: 0001539937 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35518 FILM NUMBER: 221178147 MAIL ADDRESS: STREET 1: C/O SUPERNUS PHARMACEUTICALS, INC. STREET 2: 9715 KEY WEST AVENUE CITY: ROCKVILLE STATE: MD ZIP: 20850 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SUPERNUS PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001356576 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9715 KEY WEST AVENUE CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: 301-838-2500 MAIL ADDRESS: STREET 1: 9715 KEY WEST AVENUE CITY: ROCKVILLE STATE: MD ZIP: 20850 FORMER COMPANY: FORMER CONFORMED NAME: SUPERNUS PHARMACEUTICALS INC DATE OF NAME CHANGE: 20060317 4 1 tm2223647-2_4seq1.xml OWNERSHIP DOCUMENT X0306 4 2022-08-16 0 0001356576 SUPERNUS PHARMACEUTICALS, INC. SUPN 0001539937 Khattar Jack A. C/O SUPERNUS PHARMACEUTICALS, INC. 9715 KEY WEST AVENUE ROCKVILLE MD 20850 1 1 0 0 President, CEO Common Stock 2022-08-16 4 M 0 39530 0 A 799431 D Common Stock 2022-08-16 4 M 0 9182 34.013 D 790249 D Common Stock 2022-08-16 4 S 0 14690 34.013 D 775559 D Common Stock 1047700 I By the KBT Trust Common Stock 4000 I By son Stock Appreciation Right 7.90 2022-08-16 4 M 0 39530 0 D 2023-02-05 Common Stock 39530 5895 D Transaction made pursuant to a 10b5-1 trading plan adopted June 12, 2022. Pursuant to the terms of the stock appreciation right ("SAR"), upon settlement of the SAR the Reporting Person is entitled to receive shares of common stock in an amount equal to the excess of the fair market value of the common stock on the date of exercise over the base value per share of common stock established at the time the SAR was granted. This transaction reports the number of shares of common stock equal to the difference between the number of shares underlying the exercised SAR and the number of shares issued to the Reporting Person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.00 to $34.07, inclusive. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. The Reporting Person disclaims beneficial ownership of the shares held by his son, who shares the Reporting Person's household, and this report should not be deemed an admission that the Reporting Person is the beneficial owner of his son's shares for purposes of Section 16 or for any other purpose. The stock appreciation right vested in four equal annual installments beginning on February 5, 2014. /s/ Timothy C. Dec, as attorney-in-fact 2022-08-18